Our Science

Our uniquely elegant mechanism of action provides a biotechnology platform to create precise novel product outcomes for numerous applications and allows for multiple drug administration pathways.

OUR MOA

Our active pharmaceutical ingredient permeates biofilm, a protective environment for bacteria. Biofilm allows bacteria to thrive and become drug-resistant in a way that changes the physical nature of the biofilm, thus further protecting the bacteria.

CHARACTERIZATION

  • Allotrope based on pure silver suspended in saline. (Patent 10,137,503 iss., 16,926,199 pend.)
  • Sphere
  • No ion emissions
  • 6-8 nm in diameter

OUR RESEARCH

In May 2019 we received a prestigious grant from the Cystic Fibrosis Foundation to better understand the effect of our therapeutic on the microbes that pose the greatest threats to CF patients. We partnered with Seattle Children’s Hospital and the University of Washington to conduct our studies. In October 2021 we received an additional grant from CFF to continue our research.

We partnered with Seattle Children’s Hospital and the University of Washington to conduct our studies. The studies concluded that our API is a potent and non-toxic ingredient against the most problematic pathogens in the CF community. Given these preclinical results, EVQ-218 is a unique and promising therapy for cystic fibrosis beyond Pseudomonas.

In October 2021 we received an additional grant from CFF to continue our testing. This award will support the preclinical testing of our lead asset for the treatment of multi-drug resistant pulmonary bacterial infections in patients diagnosed with cystic fibrosis.